Overactive bladder syndrome in older people

BJU International

Volumn 99, Issue 3, 2007, Pages 502-509

  Wagg, Adrian S ^a   Cardozo, Linda ^b   Chapple, Christopher ^c   De Ridder, Dirk ^d   Kelleher, Con ^e   Kirby, Michael ^f   Milsom, Ian ^g   Vierhout, Mark ^h  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cognition; Older people; Overactive bladder syndrome; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DARIFENACIN; DESMOPRESSIN; ESTROGEN; FLAVOXATE; IMIPRAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

AGE DISTRIBUTION; AGED; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; BEHAVIOR; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DETRUSOR DYSSYNERGIA; DISEASE ASSOCIATION; DRINKING BEHAVIOR; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ESTROGEN THERAPY; HUMAN; HYPONATREMIA; LIFESTYLE; LOW DRUG DOSE; MICTURITION; NURSING HOME; OVERACTIVE BLADDER; OVERACTIVE BLADDER SYNDROME; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; RELAXATION TRAINING; SHORT SURVEY; SIDE EFFECT; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; URGE INCONTINENCE; URINE INCONTINENCE; XEROSTOMIA;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 33846936010     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06677.x     Document Type: Short Survey

References (76)

1. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Wagg A, Malone-Lee J. Urinary incontinence in the elderly. Br J Urol 1998; 82 (Suppl. 1): 11-7
3. Horrocks S, Somerset M, Stoddart H, Peters TJ. What prevents older people from seeking treatment for urinary incontinence? A qualitative exploration of barriers to the use of community continence services. Fam Pract 2004; 21: 689-96
4. Shaw C, Tansey R, Jackson C, Hyde C, Allan R. Barriers to help seeking in people with urinary symptoms. Fam Pract 2001; 18: 48-52
5. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000; 6 (Suppl): S565-73
6. Malone-Lee J, Wahedna I. Characterisation of detrusor contractile function in relation to old age. Br J Urol 1993; 72: 873-80
7. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 2004; 63 (Suppl. 1): 17-23
8. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005; 144: 1089-99
9. Miller KL, DuBeau CE, Bergmann M, Griffiths DJ, Resnick NM. Quest for a detrusor overactivity index. J Urol 2002; 167: 578-85
10. Perry S, Shaw C, Assassa P et al. An epidemiological study to establish the prevalence of urinary symptoms and felt need in the community: the Leicestershire MRC Incontinence Study. J Public Health Med 2000; 22: 427-34
11. Sykes D, Castro R, Pons ME et al. Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries. Maturitas 2005; 52 (Suppl. 2): S13-23
12. Wagg A, Cohen M. Medical therapy for the overactive bladder in the elderly. Age Ageing 2002; 31: 241-6
13. Rosenberg LJ, Griffiths DJ, Resnick NM. Factors that distinguish continent from incontinent older adults with detrusor overactivity. J Urol 2005; 174: 1868-72
14. Sakakibara R, Hamano S, Uchiyama T, Liu Z, Yamanishi T, Hattori T. Do BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment. Urol Int 2005; 74: 44-50
15. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (Suppl.): S574-9
16. Wagner TH, Hu TW, Bentkover J et al. Health-related consequences of overactive bladder. Am J Manag Care 2002; 8 (Suppl.): S598-607
17. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 (Suppl.): S580-90
18. Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004; 7: 455-63
19. Serels S. The wet patient: understanding patients with overactive bladder and incontinence. Curr Med Res Opin 2004; 20: 791-801
20. Hu TW, Wagner TH. Economic considerations in overactive bladder. Am J Manag Care 2000; 6 (Suppl.): S591-8
21. Ko Y, Lin SJ, Salmon JW, Bron MS. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 2005; 11 (Suppl.): S103-11
22. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997; 26: 367-74
23. Burgio K, Locher JL, Goode PS et al. Behavioural vs drug treatment for urinary urge incontinence in older women: a randomized controlled trial. JAMA 1998; 280: 1995-2000
24. Burgio K, Locher JL, Goode PS. Combined behavioural and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-4
25. Schnelle JF, Truaghber B, Sowell MA, Newman DR, Petrilli CO, Ory M. Prompted voiding treatment of urinary incontinence in nursing home patients: a behavior management approach for nursing home staff. J Am Geriatr Soc 1989; 37: 1051-7
26. Ouslander JG, Ai-Samarrai N, Schnelle JF. Prompted voiding for nighttime incontinence in nursing homes: is it effective? J Am Geriatr Soc 2001; 49: 706-9
27. Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002; 60 (Suppl. 1): 50-5
28. Wein AJ. Urgency: the cornerstone symptom of overactive bladder. J Urol 2005; 173: 2054
29. Bemelmans BL, Kiemeney LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000; 37: 709-13
30. Szonyi G. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995; 24: 287-91
31. Malone-Lee J, Lubel D, Szonyi G. Low dose oxybutynin for the unstable bladder. BMJ 1992; 304: 1053
32. Ouslander JG, Schnelle JF, Uman G et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 1995; 43: 610-7
33. Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology 1999; 54: 420-3
34. Dmochowski RR, Davila GW, Zinner NR et al; the Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-6
35. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW; the Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 237-42
36. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacotherapy 2006; 4: 14-24
37. Chapple CR, Martinez-Garcia R, Selvaggi L et al.; for the STAR Study Group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70
38. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-10
39. Millard R, Tuttle J, Moore K et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 1551-5
40. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-5
41. Malone-Lee J, Shaffu B, Anand C, Powell C Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165: 1452-6
42. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety and tolerability of extended release once daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807
43. Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002; 168: 1027-31
44. Wagg A, Malone-Lee J. Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU Int 2003; 92: 969-71
45. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999-1004
46. Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986; 15: 299-303
47. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebocontrolled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999; 84: 646-51
48. Halaska M, Dorschner W, Frank M. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourol Urodyn 1994; 13: 428-30
49. Cardozo L, Chapple CR, Toozs-Hobson P et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000; 85: 659-64
50. Zinner N, Gittelman M, Harris R, Susset J, Kanellos A, Auerbach S; Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicentre phase III trial. J Urol 2004; 171: 2311-5
51. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392-9
52. Herberg KW. Alltags - und Verkehrrssicherheit unter Inkontinenz - Meidkation. Neue Untersuchungen zum Sicherheitspotential urologischer Anticholinergika. Med Welt 1999; 50: 217-22
53. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41: 636-44
54. Croom KF, Keating GM. Darifenacin: in the treatment of overactive bladder. Drugs Aging 2004; 21: 885-94
55. Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005; 48: 471-7
56. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173: 493-8
57. Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 2004; 83: 892-7
58. Asplund R, Sundberg B, Bergtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double blind, placebo-controlled randomized exploratory study. BJU Int 1999; 83: 591-5
59. Kuo HC. Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years. Urology 2002; 59: 485-9
60. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn 2004; 23: 302-5
61. Matthews F, Brayne C; Medical Research Council Cognitive Function and Ageing Study Investigators. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. PLoS Med 2005; 2: e193
62. Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Reglat. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol 2005; 59: 143-51
63. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195-201
64. Health and Social Care Information Centre. Prescriptions Dispensed in the Community. Statistics for 1994 to 2004: England. Statistical bulletin 2005/02. HSCIC July 2005. Available at: http://www.dh.gov.uk/assetRoot/04/11/58/87/04115887.pdf. Accessed October 2006
65. Kay G, Crook T, Rekeda L et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317-26
66. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 8-13
67. Donnellan CA, Fook L, McDonald P, Playfer JR. Oxybutynin and cognitive dysfunction. BMJ 1997; 315: 1363-4
68. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349: 2274-5
69. Movig KL, Egberts AC, Lenderink AW, Leufkens HG. Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice. J Am Geriatr Soc 2001; 49: 234-5
70. Hashimoto M, Imamura T, Tanumikai S, Kazui H, Mori E. Urinary incontinence: an unrecognized adverse effect with donepezil. Lancet 2000; 356: 568
71. Gill SS, Mandari M, Naglie G et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165: 808-13
72. Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002; 50: 1165-6
73. Siegler EL, Reidenberg M. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004; 75: 484-8
74. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005; 192: 1735-40
75. Schulte-Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66: 82-7
76. Kelly JD, Kernohan RM, Keane PF. Symptomatic outcome following clam ileocystoplasty. Eur Urol 1997; 32: 30-3